Alpha Tau Medical Ltd.

DRTS

IL0011839383

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-05 pm EDT			5-day change	1st Jan Change
9.350 ^USD	-9.14%		-13.67%	+88.89%

Jun. 04	Alpha Tau Medical Insider Sold Shares Worth $352,115, According to a Recent SEC Filing	MT
Jun. 03	Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy	MT

Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy

Published on 06/03/2026 at 10:04 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Alpha Tau Medical Ltd.

Jun. 04	Alpha Tau Medical Insider Sold Shares Worth $352,115, According to a Recent SEC Filing	MT
Jun. 03	Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy	MT
Jun. 01	Alpha Tau Medical Reports Data Showing Alpha DaRT Increases Overall Survival for Patients With Pancreatic Cancer	MT
Jun. 01	Alpha Tau Medical Ltd. Announces Strong Overall Survival Results from Alpha Dart Pancreatic Cancer Studies Presented At 2026 Asco Annual Meeting	CI
May. 28	Barclays Initiates Alpha Tau Medical With Overweight Rating, $15 Price Target	MT
May. 18	Alpha Tau Medical Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 11	Alpha Tau Says Complete Response in 2 Brain Cancer Patients Observed in Interim Trial of Radiation Treatment	MT
May. 11	Alpha Tau Medical Ltd Announces Groundbreaking Interim Results from Its U.S. Alpha DaRT Recurrent Glioblastoma Trial	CI
May. 08	Alpha Tau Medical Reaches Full Enrollment in US Pivotal Alpha DaRT Skin Cancer Study	MT
May. 08	Alpha Tau completes patient enrollment in its U.S. pivotal skin cancer study, advancing towards goal of FDA approval of Alpha Dart® to treat recurrent cutaneous squamous cell carcinoma	RE
May. 08	Alpha Tau Completes Patient Enrollment in Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of Fda Approval of Alpha Dart® to Treat Recurrent Cutaneous Squamous Cell Carcinoma	CI
May. 07	Alpha Tau Medical Ltd. Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha Dart	CI
May. 04	Alpha Tau announces 100% local disease control rate and favorable safety profile observed in Alpha Dart® pancreatic cancer trials presented at DDW 2026	RE
May. 04	Alpha Tau Medical Ltd. Presents 100% Local Disease Control Rate and Favorable Safety Profile for Alpha DaRT in Pancreatic Cancer Trials	CI
Apr. 28	Alpha Tau Medical files to offer up to $300 million in securities - SEC filing	RE

Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.

Employees

121

Sector

Advanced Medical Equipment & Technology

More about the company